2019 R&D portfolio in review: Chagas disease

Preliminary results of a Phase II study evaluating new therapeutic regimens of benznidazole showed that all treatment arms were effective and had good safety profiles. The two-week course of treatment with benznidazole alone was particularly promising, showing 83% efficacy while cutting treatment time by 75% compared to the standard eight-week treatment, with no patients discontinuing treatment due to side effects. Based on these results, DNDi is planning to run an international, multi-site confirmatory Phase III study.

Brazil’s Ministry of Health and CNPq to invest in researching new treatments for leishmaniasis and Chagas disease

Brasilia, Brazil – 5 December 2019
Studies may lead to therapeutic alternatives for people living with these neglected tropical diseases
The Brazilian Ministry of Health (the Department of Science and Technology of the Science, Technology and Strategic Inputs Secretariat – Decit/SCTIE) and CNPq (National Council for Scientific and Technological Development) will invest around R$ 1,5 million (US$ 370,000) in research that may lead to the development of a new treatment option for cutaneous leishmaniasis.

ASTMH 2019

68th Annual Meeting

20-24 November 2019
National Harbor, USA

  • Symposium on tools to accelerate elimination of onchocerciasis
  • Presentations on onchocerciasis, lymphatic filariasis, leishmaniasis, clinical trials, and Chagas disease.

Lack of awareness of Chagas disease in the US leading to unnecessary deaths in vulnerable immigrant communities

New York/Los Angeles – 26 September 2019
New DNDi/CECD/MSF paper published in PLOS Neglected Tropical Diseases on the “silent killer” Chagas disease
Fear, stigma, gaps in the health system, and lack of awareness in the medical community are among the barriers keeping the most vulnerable from accessing essential care for Chagas disease, a leading cause of heart disease in the Americas, according to a paper published today by the not-for-profit drug development organization DNDi, the Center of Excellence for Chagas Disease, and the international medical humanitarian organization MSF.

La falta de concientización sobre la enfermedad de Chagas en los EEUU está causando muertes prevenibles en comunidades de inmigrantes vulnerables

Nueva York/Los Ángeles – 26 September 2019
Nuevo artículo de DNDi/CECD/MSF publicado en PLOS Neglected Tropical Diseases sobre la enfermedad de Chagas, “el asesino silencioso”.
El miedo, las brechas en el sistema de salud y la falta de concientización son algunas de las barreras que impiden el acceso de los más vulnerables al tratamiento de la enfermedad de Chagas, una de las principales causas de problemas cardíacos en las Américas, según un artículo publicado por la organización sin fines de lucro de desarrollo de medicamentos iniciativa Medicamentos para Enfermedades Olvidadas (DNDi, por su acrónimo en inglés), el Center of Excellence for Chagas Disease (CECD) del centro médico Olive View de la UCLA y la organización humanitaria médica internacional Médicos Sin Fronteras (MSF).

Chagas Disease. A clinical approach

This book offers a comprehensive overview of Chagas disease, including its vectorial and congenital transmission, and molecular diagnosis, which is essential for screening, and developing and providing timely, effective anti-trypanosomal treatment.

SpringerLink, September 2019

La Nacion  [22 August 2019]

“Enfermedad de Chagas: la transmisión materna ya origina más casos que la vinchuca” – “Chagas disease: congenital transmission already is the source of more cases than the vinchuca”

Click here to read the article